Lilly Asia Ventures

Founded 2008

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 120
Average round size
info
The average size of a deal this fund participated in
$60M
Portfolio companies 80
Rounds per year 9.23
Lead investments 23
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.38
Exits 25
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Biopharma
Summary

In 2008 was created Lilly Asia Ventures, which is appeared as VC. The main office of represented VC is situated in the Shanghai. The venture was found in Asia in China.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Lilly Asia Ventures, startups are often financed by OrbiMed, ARCH Venture Partners, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Vivo Capital, Temasek Holdings. In the next rounds fund is usually obtained by Hillhouse Capital Group, Qiming Venture Partners, Temasek Holdings.

The overall number of key employees were 4.

We can highlight the next thriving fund investment areas, such as Biotechnology, Health Care. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Innovent Biologics, Alector, Betta Pharmaceuticals. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

The high activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. Opposing the other organizations, this Lilly Asia Ventures works on 15 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 16 percentage points more often commits exit comparing to other companies. The average startup value when the investment from Lilly Asia Ventures is 500 millions - 1 billion dollars.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

LYNK Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$50M27 Aug 2021 Hangzhou, Zhejiang, China

Ionova Life Science

Biotechnology
Health Care
$100M22 Aug 2021 Futian District, Guangdong Province, China

MediTrust Health

Health Care
Internet
Medical
$309M09 Aug 2021 Minhang District, China

Zentera Therapeutics

Biotechnology
Pharmaceutical
$75M04 Aug 2021 Shanghai, Shanghai, China

Pulnovo Medical

Medical
Medical Device
$15M03 Aug 2021 Wuxi, Anhui, China

Neukio Biotherapeutics

Biotechnology
$40M29 Jul 2021 Shanghai, Shanghai, China

ProfoundBio

Biotechnology
Therapeutics
$55M12 Jul 2021 Suzhou, Jiangsu, China

ArriVent Biopharma

Biotechnology
Pharmaceutical
$90M30 Jun 2021 Pennsylvania Furnace, Pennsylvania, United States

Insilico Medicine

Artificial Intelligence
Biotechnology
Genetics
Health Care
Pharmaceutical
$255M22 Jun 2021 Hong Kong Island, Hong Kong, China
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

ADARx Raises $75 Million to Advance Growing Pipeline

– ADARx Pharmaceuticals, Inc. completed a $75m Series B financing.
– The round was co-led by SR One Capital Management and OrbiMed Advisors.
Sirona Capital joined this financing as well as existing investor Lilly Asia Ventures.
– The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
– The proceeds will also be used to transition ADARx’s growing pipeline of research phase products into the clinic including initiation of a Phase 1 clinical trial for ADARx’s lead program.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Lilly Asia Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: